We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+22.48%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$143M
AUM Growth
+$1.74M
Cap. Flow
-$14.9M
Cap. Flow %
-10.35%
Top 10 Hldgs %
73.75%
Holding
32
New
5
Increased
9
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
AVBP icon
ArriVent BioPharma
AVBP
+$6.45M
2
WHWK
Whitehawk Therapeutics
WHWK
+$5.31M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$4.95M
4
AVLN
Avalyn Pharma
AVLN
+$3.32M
5
ARTV
Artiva Biotherapeutics
ARTV
+$2.37M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$26.1M
2
OCS icon
Oculis Holding
OCS
+$2.61M
3
RVMD icon
Revolution Medicines
RVMD
+$2.54M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$1.61M
5
DRUG
Bright Minds Biosciences
DRUG
+$1.51M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$9.63B
$27.7M 19.32%
82,796
-2,105
-2% -$666K
WHWK
2
Whitehawk Therapeutics
WHWK
$263M
$21.5M 14.96%
4,685,912
+1,275,510
+37% +$5.31M
TNGX icon
3
Tango Therapeutics
TNGX
$3.94B
$12.2M 8.52%
390,949
-50,882
-12% -$1.26M
STRO icon
4
Sutro Biopharma
STRO
$339M
$8.97M 6.25%
270,251
+826
+0.3% +$25.8K
AVBP icon
5
ArriVent BioPharma
AVBP
$1.49B
$7.6M 5.29%
+218,694
New +$6.45M
FDMT icon
6
4D Molecular Therapeutics
FDMT
$810M
$6.75M 4.71%
+507,801
New +$4.95M
DRUG
7
Bright Minds Biosciences
DRUG
$714M
$6.51M 4.54%
92,745
-19,251
-17% -$1.51M
OCUL icon
8
Ocular Therapeutix
OCUL
$2.28B
$5.23M 3.64%
532,481
-59,627
-10% -$540K
ERAS icon
9
Erasca
ERAS
$6.31B
$4.86M 3.39%
265,199
-89,376
-25% -$1.28M
SRZN icon
10
Surrozen
SRZN
$264M
$4.5M 3.14%
173,395
+548
+0.3% +$15.1K
ARGX icon
11
argenx
ARGX
$64B
$4.37M 3.04%
4,705
+15
+0.3% +$12.4K
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$1.28B
$4.2M 2.93%
215,652
+23,892
+12% +$433K
DSGN icon
13
Design Therapeutics
DSGN
$946M
$4.09M 2.85%
282,564
+136,664
+94% +$1.7M
NERV icon
14
Minerva Neurosciences
NERV
$231M
$3.94M 2.74%
709,500
– –
TSHA icon
15
Taysha Gene Therapies
TSHA
$1.88B
$3.83M 2.67%
561,808
+122,344
+28% +$724K
AVLN
16
Avalyn Pharma
AVLN
$1.54B
$3.79M 2.64%
+115,000
New +$3.32M
AVTX icon
17
Avalo Therapeutics
AVTX
$1.05B
$3.44M 2.4%
186,308
+125,500
+206% +$1.98M
AMLX icon
18
Amylyx Pharmaceuticals
AMLX
$3.87B
$3.02M 2.1%
168,115
+17,048
+11% +$264K
ARTV
19
Artiva Biotherapeutics
ARTV
$542M
$2.53M 1.76%
+260,416
New +$2.37M
CMPX icon
20
Compass Therapeutics
CMPX
$432M
$1.3M 0.91%
595,213
-253,863
-30% -$749K
UTHR icon
21
United Therapeutics
UTHR
$22.1B
$1.21M 0.84%
2,224
– –
CTNM
22
Contineum Therapeutics
CTNM
$641M
$1.03M 0.72%
+63,095
New +$827K
LBRX
23
LB Pharmaceuticals
LBRX
$1.54B
$939K 0.65%
28,919
– –
IDYA icon
24
CALL
IDEAYA Biosciences
IDYA
$3.87B
– –
-350
Closed -$1.17M
IDYA icon
25
IDEAYA Biosciences
IDYA
$3.87B
– –
-48,234
Closed -$1.61M
1
2

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Acuta Capital Partners held 32 positions worth $143M, up 1.2% from $142M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Acuta Capital Partners withdrew a net $14.9M in Q2 2026, closing 9 positions and reducing 6 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $26.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in ArriVent BioPharma worth $7.6M.

  • Acuta Capital Partners's largest Q2 2026 buy was ArriVent BioPharma: 218,694 shares worth $7.6M.
  • Acuta Capital Partners added most to Whitehawk Therapeutics in Q2 2026, an estimated $5.31M increase.
  • Acuta Capital Partners's biggest Q2 2026 reduction was Bright Minds Biosciences, cutting an estimated $1.51M.
  • Acuta Capital Partners fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $26.1M.
  • Acuta Capital Partners's ten largest holdings make up 74% of its $143M portfolio in Q2 2026.
  • Acuta Capital Partners opened 5 new positions and closed 9 in Q2 2026.
  • Acuta Capital Partners's portfolio value rose 1.2% quarter-over-quarter to $143M.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.